CITATION REPORT List of articles citing

Mendelian randomization of blood lipids for coronary heart disease

DOI: 10.1093/eurheartj/eht571 European Heart Journal, 2015, 36, 539-50.

Source: https://exaly.com/paper-pdf/62306990/citation-report.pdf

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
498	Mendelian randomization: genetic anchors for causal inference in epidemiological studies. 2014 , 23, R89-98		1045
497	Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application. 2014 , 5, 455		25
496	High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle. 2014 , 237, 838-9		
495	HDL-targeted therapies: progress, failures and future. 2014 , 13, 445-64		233
494	Skin pigmentation, sun exposure and vitamin D levels in children of the Avon Longitudinal Study of Parents and Children. 2014 , 14, 597		28
493	Atherosclerosis: Is a cure in sight?. 2015 , 9, S1-4		2
492	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. 2015 , 278, 433-46		26
491	Exploring causal associations of alcohol with cardiovascular and metabolic risk factors in a Chinese population using Mendelian randomization analysis. 2015 , 5, 14005		31
490	MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. 2015 , 5, 16645		57
489	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. 2015 ,		4
488	The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. 2015 , 62, 1742-56		104
487	Targeting Abdominal Adiposity and Cardiorespiratory Fitness in the Workplace. 2015, 47, 1342-50		10
486	HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. 2015 , 6, 187		22
485	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. <i>European Heart Journal</i> , 2015 , 36, 1424-7	9.5	3
484	Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. 2015 , 181, 251-60		387
483	A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. 2015 , 64, 3028-36		79
482	How to Control Residual Risk During the Statin Era?. 2015 , 66, 1848		6

481	Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?. 2015 , 131, 225-7	13
480	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. 2015 , 64, 2344-5	6
479	Common variants associated with blood lipid levels do not affect carotid plaque composition. 2015 , 242, 351-6	3
478	Butter increased total and LDL cholesterol compared with olive oil but resulted in higher HDL cholesterol compared with a habitual diet. 2015 , 102, 309-15	35
477	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. 2015 , 17, 610	7
476	Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. 2015 , 101, 847-53	13
475	Lipoproteins and diabetes. European Heart Journal, 2015 , 36, 529-31	1
474	Epidemiology: disease associations and modulators of HDL-related biomarkers. 2015 , 224, 259-83	4
473	Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. 2015 , 16, 54	31
472	Postprandial Plasma Phospholipids in Men Are Influenced by the Source of Dietary Fat. 2015 , 145, 2012-8	43
471	Lipids in Coronary Heart Disease. 2016 , 67-80	
470	Cholesterol as a Risk Factor for Subarachnoid Hemorrhage: A Systematic Review. 2016 , 11, e0152568	22
469	Novel therapies for severe dyslipidemia originating from human genetics. 2016 , 27, 112-24	15
468	Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say. 2016 , 70, 142-6	
467	Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?. 2016 , 18, 67	55
466	Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients. 2015 , 6, 73-82	13
465	The multifaceted interplay between lipids and epigenetics. 2016 , 27, 288-94	8
464	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. 2016 , 18, 65	12

463	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. 2016 , 118, 138-45	92
462	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. 2016 , 135, 453-467	9
461	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. 2016 , 48, 634-9	162
460	Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects. 2016 , 9, 231-9	20
459	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016, 253, 281-344	519
458	Genetic analysis of atherosclerosis identifies a major susceptibility locus in the major histocompatibility complex of mice. 2016 , 254, 124-132	10
457	Genetic analysis of emerging risk factors in coronary artery disease. 2016 , 254, 35-41	10
456	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. 2016 , 128, 859-864	4
455	[Impact of lipid metabolism parameters on the development and progression of coronary artery disease: An update]. 2016 , 41, 273-80	3
454	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. 2016 , 1, 692-9	168
453	Blood lipids and prostate cancer: a Mendelian randomization analysis. 2016 , 5, 1125-36	45
452	Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. 2016 , 40, 304-14	1425
451	Polygenic Epidemiology. 2016 , 40, 268-72	93
450	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016 , 37, 2999 ₃₋₃ 05	81781
449	Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids. 2016 , 15, 115	9
448	Genetic support for the causal role of insulin in coronary heart disease. 2016 , 59, 2369-2377	11
447	Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. 2016 , 17, 1621-1628	8
446	Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. 2016 , 45, 1961-1974	387

(2016-2016)

445	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. 2016 , 125, 57-64		25
444	Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. 2016 , 253, 171-177		29
443	The C1431T polymorphism of peroxisome proliferator activated receptor [[PPAR]] is associated with low risk of diabetes in a Pakistani cohort. 2016 , 8, 67		7
442	Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines. <i>European Heart Journal</i> , 2016 , 37, 2963-2965).5	1
441	HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics. 2016 , 18, 71		7
440	Functionality of High-Density Lipoprotein as Antiatherosclerotic Therapeutic Target. 2016 , 36, e87-e94		12
439	Increasing insulin resistance accentuates the effect of triglyceride-associated loci on serum triglycerides during 5 years. 2016 , 57, 2193-2199		2
438	Genetic susceptibility to dyslipidemia and incidence of cardiovascular disease depending on a diet quality index in the MalmDiet and Cancer cohort. 2016 , 11, 20		2
437	HDL infusion for the management of atherosclerosis: current developments and new directions. 2016 , 27, 592-596		10
436	The impact of common polymorphisms in CETP and ABCA1 genes with the risk of coronary artery disease in Saudi Arabians. 2016 , 10, 8		14
435	Adding Mendelian randomization to a meta-analysis-a burgeoning opportunity. 2016 , 37, 1527-9		2
434	Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II. 2016 , 15, 83		12
433	Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. 2016 , 45, 1600-1616		114
432	Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. 2016 , 45, 1927-1937		65
431	Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future. 2016 , 23, 124-30		43
430	Do Genetic Factors Modify the Relationship Between Obesity and Hypertriglyceridemia? Findings From the GLACIER and the MDC Studies. 2016 , 9, 162-71		6
429	Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. 2016, 30, 1-11		4
428	Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. 2016 , 103, 965-78		245

427	Light-to-moderate drinking and incident heart failurethe Norwegian HUNT study. 2016 , 203, 553-60	9
426	Dysfunctional HDL and atherosclerotic cardiovascular disease. 2016 , 13, 48-60	384
425	Novel Risk Markers and Risk Assessments for Cardiovascular Disease. 2017 , 120, 133-149	80
424	High-density lipoproteins in high resolution: Will proteomics solve the paradox for cardiovascular risk?. 2017 , 17, 1600426	2
423	Genetic analysis of a mouse cross implicates an anti-inflammatory gene in control of atherosclerosis susceptibility. 2017 , 28, 90-99	7
422	'Mendelian randomization': an approach for exploring causal relations in epidemiology. 2017 , 145, 113-119	21
421	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. 2017 , 69, 823-836	146
420	Kardiovaskuli wirksame Therapie bei Patienten mit Diabetes mellitus. 2017 , 13, 100-107	1
419	Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. 2017 , 11, 725-732.e5	57
418	Increasing HDL-C levels with medication: current perspectives. 2017 , 28, 361-366	6
417	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis 9.5 Society Consensus Panel. <i>European Heart Journal</i> , 2017 , 38, 2459-2472	1267
416	Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes. 2017 , 60, 1234-1243	13
415	Human genetic insights into lipoproteins and risk of cardiometabolic disease. 2017 , 28, 113-119	9
414	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. 2017 , 70, 754-762	3
413	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 2017 , 136, e1-e23	587
412	Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. 2017 , 28, 30-42	318
	Matciple deficite variancs. 2011, 20, 30 42	
411	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 2017 , 376, 1933-1942	406

409	Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. 2017, 6,	65
408	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. 2017 , 14, 577-590	245
407	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. 2017 , 140, 2701-2708	50
406	Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. 2017 , 7, 360	18
405	TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. 2017 , 23, 100-112	32
404	Hypertriglyceridaemia and risk of coronary artery disease. 2017 , 14, 401-411	178
403	Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. 2017 , 11, 646-656	8
402	The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. 2017 , 60, 2210-2220	38
401	Shared polymorphisms and modifiable behavior factors for myocardial infarction and high cholesterol in a retrospective population study. 2017 , 96, e7683	1
400	Gentlica de la cardiopatti isquíhica: del conocimiento actual a las implicaciones clílicas. 2017, 70, 754-762	6
399	GenEica de la cardiopat isquinica: del conocimiento actual a las implicaciones cliticas. 2017, 70, 754-762 Recent Developments in Mendelian Randomization Studies. 2017, 4, 330-345	218
399	Recent Developments in Mendelian Randomization Studies. 2017 , 4, 330-345 Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular	218
399	Recent Developments in Mendelian Randomization Studies. 2017, 4, 330-345 Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). 2017, 10, Correcting the Standard Errors of 2-Stage Residual Inclusion Estimators for Mendelian	218 5
399 398 397	Recent Developments in Mendelian Randomization Studies. 2017, 4, 330-345 Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). 2017, 10, Correcting the Standard Errors of 2-Stage Residual Inclusion Estimators for Mendelian Randomization Studies. 2017, 186, 1104-1114 Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma	21858
399 398 397 396	Recent Developments in Mendelian Randomization Studies. 2017, 4, 330-345 Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). 2017, 10, Correcting the Standard Errors of 2-Stage Residual Inclusion Estimators for Mendelian Randomization Studies. 2017, 186, 1104-1114 Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. 2017, 17, 222-229 Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.	218587
399 398 397 396 395	Recent Developments in Mendelian Randomization Studies. 2017, 4, 330-345 Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). 2017, 10, Correcting the Standard Errors of 2-Stage Residual Inclusion Estimators for Mendelian Randomization Studies. 2017, 186, 1104-1114 Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. 2017, 17, 222-229 Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. 2017, 19, 61	2185879

391	Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?. 2017 , 42 Suppl 12, 3-9	1
390	Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. 2017 , 4, e000731	1
389	Metabolic Profiling of Adiponectin Levels in Adults: Mendelian Randomization Analysis. 2017, 10,	16
388	Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia. 2017 , 7, 17921	14
387	Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. 2017 , 15, 218	45
386	Gene Polymorphisms and Gene Expression Associated with Coronary Artery Disease. 2017 , 2017, 4138376	7
385	Hypertriglyceridemia and atherosclerosis. 2017 , 16, 233	102
384	Low-carbohydrate diets for the treatment of obesity and type 2 diabetes. 2018 , 21, 308-312	23
383	From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. 2018 , 114, 1192-1208	36
382	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. <i>European Heart Journal</i> , 2018 , 39, 354-359	28
381	Challenges in Interpreting Multivariable Mendelian Randomization: Might "Good Cholesterol" Be Good After All?. 2018 , 71, 149-153	12
380	Is a fatty liver (always or ever) bad for the heart?. <i>European Heart Journal</i> , 2018 , 39, 394-396 9.5	3
379	Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. 2018, 71, 620-632	162
378	From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. 2018 , 38, 487-499	59
377	Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals. 2018 , 38, 660-668	41
376	Machine learning in cardiovascular medicine: are we there yet?. 2018 , 104, 1156-1164	195
375	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. 2018 , 269, 92-99	8
374	Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. 2018 , 38, 292-303	151

(2018-2018)

373	Mendelian randomization with Egger pleiotropy correction and weakly informative Bayesian priors. 2018 , 47, 1217-1228	11
372	Pharmacogenomics of blood lipid regulation. 2018 , 19, 651-665	1
371	Polygenic link between blood lipids and amyotrophic lateral sclerosis. 2018, 67, 202.e1-202.e6	25
370	Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies. 2018 , 36, 203-211	21
369	The Pros and Cons of Mendelian Randomization Studies to Evaluate Emerging Cardiovascular Risk Factors. 2018 , 12, 1	O
368	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study. 2018 , 49, 820-827	70
367	HDLs and the pathogenesis of atherosclerosis. 2018 , 33, 311-316	12
366	Novel Approaches to Cardiovascular Diagnostics. 2018 , 83-101	
365	HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. 2018 , 71, 166-172	59
364	Association between Mediterranean diet adherence and dyslipidaemia in a cohort of adults living in the Mediterranean area. 2018 , 69, 608-618	18
363	Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study. 2018 , 107, 74-86	11
362	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. 2018 , 103, 409-418	26
361	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. 2018 , 3, 26-33	44
360	Effect of whole milk compared with skimmed milk on fasting blood lipids in healthy adults: a 3-week randomized crossover study. 2018 , 72, 249-254	21
359	Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. 2018 , 3, 34-43	33
358	Association of total cholesterol, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol with atherosclerotic cardiovascular disease and cancer in a Chinese male population. 2018 , 142, 1209-1217	10
357	Coronary artery disease, genetic risk and the metabolome in young individuals. 2018, 3, 114	13
356	Standard and Novel Biomarkers. 2018 , 98-113	1

355	The pleiotropic vasoprotective functions of high density lipoproteins (HDL). 2017,	11
354	OBSOLETE: Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. 2018,	
353	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. 2018 , 48, 1097-1119	10
352	Associations of Body Mass and Fat Indexes With Cardiometabolic Traits. 2018 , 72, 3142-3154	52
351	Bivariate Genome-Wide Association Scan Identifies 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease. 2018 , 11, e002239	16
350	Current concepts in atherosclerosis. 2018 , 34, 198-205	1
349	Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. 2018, 221-229	
348	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. 2018 , 206, 80-93	183
347	Genome-wide analysis in multiple-case families: assessing the relationship between triglyceride and methylation. 2018 , 12, 33	
346	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. 2018 , 7, e008740	58
345	Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study. 2018 , 15, e1002649	24
344	High-density lipoprotein (HDL) cholesterol - more complicated than we think?. 2018 , 25, 517-526	7
343	A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure. 2018 , 42, 636-647	2
342	Diabetes alters the association between high-density lipoprotein subfractions and carotid intima-media thickness: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2018 , 15, 541-547	4
341	Food groups and intermediate disease markers: a systematic review and network meta-analysis of randomized trials. 2018 , 108, 576-586	49
340	Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?. 2018 , 5, e000789	6
339	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. 2018 , 59, 1266-1275	36
338	Genetic-Driven Druggable Target Identification and Validation. 2018 , 34, 558-570	25

337	Strikingly Different Atheroprotective Effects of Apolipoprotein A-I in Early-Versus Late-Stage Atherosclerosis. 2018 , 3, 187-199	7
336	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. 2018 , 12, 1290-1297.e1	7
335	LDL Cholesterol Rises With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data. 2018 , 41, 2195-2201	17
334	Serum magnesium levels and risk of coronary artery disease: Mendelian randomisation study. 2018 , 16, 68	21
333	Common Methods for Performing Mendelian Randomization. 2018 , 5, 51	47
332	Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease. 2018 , 5, 56	12
331	Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. 2018 , 362, k601	576
330	Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. 2018 , 59, 1771-1782	56
329	Evaluation of the relationship between plasma lipids and abdominal aortic aneurysm: A Mendelian randomization study. 2018 , 13, e0195719	26
328	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. 2018, 19,	19
327	Analysis of causal effect of APOA5 variants on premature coronary artery disease. 2018, 82, 437-447	6
326	Association of longitudinal alcohol consumption trajectories with coronary heart disease: a meta-analysis of six cohort studies using individual participant data. 2018 , 16, 124	20
325	Genetic and Epigenetic Regulations of Post-prandial Lipemia. 2018, 6, 124-131	
324	Extending Causality Tests with Genetic Instruments: An Integration of Mendelian Randomization with the Classical Twin Design. 2018 , 48, 337-349	32
323	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. 2019 , 105, 568-581	3
322	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. 2019 ,	25
321	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. 2019 , 21, 110	11
320	Impact of different types of olive oil on cardiovascular risk factors: A´systematic review and network meta-analysis. 2019 , 29, 1030-1039	33

319	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. 2019 , 26, 1512-1524	13
318	Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. 2019 , 48, 1478-1492	39
317	rs6882076 SNP Is Associated with Decreased Levels of Triglycerides and the Risk of Coronary Heart Disease and Ischemic Stroke. 2019 , 16, 864-871	5
316	Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine. 2019 , 10, 195-209	14
315	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. 2019 , 42, 829	9
314	Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. 2019 , 9, 14426	12
313	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. 2019 , 50, 362-367	5
312	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. 2019 , 10, 5121	31
311	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. 2019 , 39, e1-e9	19
310	A comprehensive study of metabolite genetics reveals strong pleiotropy and heterogeneity across time and context. 2019 , 10, 4788	25
309	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. 2019 , 94, 1670-1680	31
308	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205	259
307	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. 2019 , 322, 1381-1391	79
306	Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause. 2019 , 9, 13407	8
305	Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. 2019 , 139, e56-e528	3937
304	Prioritizing putative influential genes in cardiovascular disease susceptibility by applying tissue-specific Mendelian randomization. 2019 , 11, 6	19
303	HDL cholesterol and ASCVD risk stratification: A debate. 2019 , 283, 7-12	27
302	Impact of different dietary approaches on blood lipid control in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. 2019 , 34, 837-852	16

301	Associations of food groups and cardiometabolic and inflammatory biomarkers: does the meal matter?. 2019 , 122, 707-716	7
300	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. 2019 , 62, 758-770	5
299	Direct Estimation of HDL-Mediated Cholesterol Efflux Capacity from Serum. 2019 , 65, 1042-1050	9
298	Association between resting heart rate and incident diabetes risk: a Mendelian randomization study. 2019 , 56, 1037-1044	9
297	Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects. 2019 , 10, 1941	52
296	Metabolomic and lipidomic assessment of the metabolic syndrome in Dutch middle-aged individuals reveals novel biological signatures separating health and disease. 2019 , 15, 23	24
295	Triglycerides: Mendelian Randomization Studies Suggest Causal Role, but How to Treat in 2019?. 2019 , 13, 1	
294	Rethinking good cholesterol: a clinicians' guide to understanding HDL. 2019 , 7, 575-582	20
293	Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. 2019 , 106, 960-967	О
292	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. 2019 , 40, 537-557	109
291	Vasoprotective Functions of High-Density Lipoproteins Relevant to Alzheimer's Disease Are Partially Conserved in Apolipoprotein B-Depleted Plasma. 2019 , 20,	4
2 90	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. 2019 , 13, 492-501	O
289	Mendelian Randomization Analysis Support Causal Associations of HbA1c with Circulating Triglyceride, Total and Low-density Lipoprotein Cholesterol in a Chinese Population. 2019 , 9, 5525	3
288	Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. 2019 , 92, e1176-e1187	16
287	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 2019 , 19, 13	14
286	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. 2019 , 17, e3000572	15
285	Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. 2019 , 13, 744-753.e15	10
	Veceralis. 2017, 15, 111 155.015	

283	High-density lipoprotein: our elusive friend. 2019 , 30, 314-319	7
282	HDL from an Alzheimer's disease perspective. 2019 , 30, 224-234	38
281	Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation. 2019 , 12, e002711	41
280	Can atherosclerosis be cured?. 2019 , 30, 477-484	5
279	Triglycerides and endothelial function: molecular biology to clinical perspective. 2019, 30, 364-369	5
278	Genetics of early-onset coronary artery disease: from discovery to clinical translation. 2019 , 34, 706-713	5
277	Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. 2019, 139, 256-268	67
276	Association of long-term PM exposure with traditional and novel lipid measures related to cardiovascular disease risk. 2019 , 122, 193-200	38
275	Potential causal associations of serum 25-hydroxyvitamin D with lipids: a Mendelian randomization approach of the HUNT study. 2019 , 34, 57-66	8
274	Deciphering Cardiovascular Genomics and How They Apply to Cardiovascular Disease Prevention. 2019 , 99-111	
²⁷⁴ ²⁷³		11
	2019, 99-111 Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause	11 2236
273	2019, 99-111 Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause Mortality: A Nationwide Population-Based Cohort Study. 2020, 75, 2200-2206 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce	
273 272	2019, 99-111 Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause Mortality: A Nationwide Population-Based Cohort Study. 2020, 75, 2200-2206 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188	2236
273 272 271	Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause Mortality: A Nationwide Population-Based Cohort Study. 2020, 75, 2200-2206 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188 9.5 A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. 2020, 49, 1117-1131 Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in	2236 17
273 272 271 270	Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause Mortality: A Nationwide Population-Based Cohort Study. 2020, 75, 2200-2206 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188 9-5 A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. 2020, 49, 1117-1131 Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. 2020, 5, 13-20 Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world	2236 17 15
273 272 271 270 269	Longitudinal Changes in Depressive Symptoms and Risks of Cardiovascular Disease and All-Cause Mortality: A Nationwide Population-Based Cohort Study. 2020, 75, 2200-2206 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188 9.5 A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. 2020, 49, 1117-1131 Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. 2020, 5, 13-20 Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. 2020, 22, 279-289 The Causal Relationship of Circulating Triglyceride and Glycated Hemoglobin: A Mendelian	2236 17 15

(2020-2020)

265	Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature. 2020 , 9, 2048004020949326	6
264	Commentary: Using human genetics to guide the repurposing of medicines. 2020 , 49, 1140-1146	2
263	Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. 2020 , 76, 2712-2724	58
262	Mendelian randomization and pleiotropy analysis. 2021 , 9, 122-132	5
261	An iterative approach to detect pleiotropy and perform Mendelian Randomization analysis using GWAS summary statistics. 2021 , 37, 1390-1400	8
260	Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor. 2020 , 11, 554931	2
259	High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions. 2020 , 8,	8
258	Effets de la corticothfapie systfhique sur le mfabolisme des HDL. 2020 , 14, 529-535	
257	Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study. 2020 , 19, 173	1
256	High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study. 2020 , 112, 154351	10
256 255		10
	study. 2020 , 112, 154351 Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A	
255	Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial. 2020 , 17,	4
255 254	Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial. 2020, 17, High-Density Lipoprotein-Targeted Therapies for Heart Failure. 2020, 8, High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort	3
255 254 253	Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial. 2020, 17, High-Density Lipoprotein-Targeted Therapies for Heart Failure. 2020, 8, High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults. 2021, 50, 902-913	437
255 254 253 252	Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial. 2020, 17, High-Density Lipoprotein-Targeted Therapies for Heart Failure. 2020, 8, High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults. 2021, 50, 902-913 [Hypercholesterolemia - the way to lower LDL-C 2020, 162, 36-42	4 3 7
255 254 253 252 251	Effect of a Graduated Walking Program on the Severity of Obstructive Sleep Apnea Syndrome. A Randomized Clinical Trial. 2020, 17, High-Density Lipoprotein-Targeted Therapies for Heart Failure. 2020, 8, High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults. 2021, 50, 902-913 [Hypercholesterolemia - the way to lower LDL-C 2020, 162, 36-42 Regional Variation in Genetic Control of Atherosclerosis in Hyperlipidemic Mice. 2020, 10, 4679-4689	4 3 7 1 3

247	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. 2020 , 159, 54-93	10
246	Exploring the causal pathway from body mass index to coronary heart disease: a network Mendelian randomization study. 2020 , 11, 2040622320909040	5
245	Leisure time physical activity is associated with improved HDL functionality in high cardiovascular risk individuals: a cohort study. 2020 , 2047487320925625	6
244	Genomics of hypertriglyceridemia. 2020 , 97, 141-169	3
243	In-depth Mendelian randomization analysis of causal factors for coronary artery disease. 2020 , 10, 9208	2
242	Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. 2020 , 19, 28	13
241	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. 2020 , 8,	6
240	Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. 2020 , 17, e1003062	127
239	Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study. 2020 , 313, 99-104	16
238	Association Between Atherosclerosis and Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus. 2020 , 13, 1911-1920	3
237	Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk. 2020 , 2020, 5950813	4
236	High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. 2020 , 18, 176-185	35
235	Genomic prediction of alcohol-related morbidity and mortality. 2020 , 10, 23	7
234	Body fat percentage and CRP correlates with a composite score of vascular risk markers in healthy, young adults - The Lifestyle, Biomarkers, and Atherosclerosis (LBA) study. 2020 , 20, 77	2
233	Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. 2020 , 299, 56-63	27
232	Can Body Fat Cause Aortic Stenosis?: Lessons From Genetics. 2020 , 75, 177-179	
231	Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. 2020 , 143, 597-610	17
230	Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested Case-Control Study. 2020 , 141, 444-453	28

(2021-2020)

229	Association of four lipid components with mortality, myocardial infarction, and stroke in statin-nalle young adults: A nationwide cohort study. 2020 , 27, 870-881	12
228	Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. 2020 , 74, e13508	5
227	High-Density Lipoproteins Are Bug Scavengers. 2020 , 10,	23
226	Correlation without a cause: an epidemiological odyssey. 2020 , 49, 4-14	21
225	High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. 2020 , 302, 36-42	24
224	Galactose Ingested with a High-Fat Beverage Increases Postprandial Lipemia Compared with Glucose but Not Fructose Ingestion in Healthy Men. 2020 , 150, 1765-1772	2
223	High-density lipoproteins during sepsis: from bench to bedside. 2020 , 24, 134	50
222	Impact of intermittent energy restriction on anthropometric outcomes and intermediate disease markers in patients with overweight and obesity: systematic review and meta-analyses. 2021 , 61, 1293-1304	7
221	Using off-target data from whole-exome sequencing to improve genotyping accuracy, association analysis and polygenic risk prediction. 2021 , 22,	3
220	Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice. 2021 , 56, 17-29	4
219	Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. 2021 , 62, 100044	13
218	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. 2021 , 31, 49-56	6
217	Precision Medicine and Informatics. 2021 , 941-966	
216	Prevention of Cardiovascular Disease. 2021 , 33-54	
215	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. 2021 , 64, 668-680	5
214	Biomarkers. 2021 , 31-64	
213	Genetics. 2021 , 65-80	
212	Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. 2021 , 13, 29	3

211	Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease. 2021 , 10,	3
2 10	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. 2021 , 18, 435-453	16
209	Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. 2021 , 23, 27	3
208	Prospective Study on Plasma MicroRNA-4286 and Incident Acute Coronary Syndrome. 2021 , 10, e018999	4
207	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. 2021 , 23, 16	1
206	Triglycerides and cardiovascular disease. 2021 , 36, 469-477	2
205	Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk. 2021 ,	Ο
204	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. 2021 , 10,	6
203	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. 2021 , 12, 2182	5
202	Coronary heart disease risk: Low-density lipoprotein and beyond. 2021,	6
201	LDL cholesterol and atherosclerosis: The evidence. 2021 , 33 Suppl 1, 25-32	2
200	Postprandial Lipid Metabolism in Normolipidemic Subjects and Patients with Mild to Moderate Hypertriglyceridemia: Effects of Test Meals Containing Saturated Fatty Acids, Mono-Unsaturated Fatty Acids, or Medium-Chain Fatty Acids. 2021 , 13,	1
199	Recent Molecular Mechanisms and Beneficial Effects of Phytochemicals and Plant-Based Whole Foods in Reducing LDL-C and Preventing Cardiovascular Disease. 2021 , 10,	5
198	Distinct Fatty Acid Compositions of HDL Phospholipids Are Characteristic of Metabolic Syndrome and Premature Coronary Heart Disease-Family Study. 2021 , 22,	5
197	Hepatocyte Small Heterodimer Partner Mediates Sex-Specific Effects on Triglyceride Metabolism via Androgen Receptor in Male Mice. 2021 , 11,	1
196	Incidence and Predictors of Cardiovascular Disease among Type 1 and Type 2 Diabetes Mellitus in a Tertiary Health Care Setting of Ethiopia: 8-Year Retrospective Follow-Up Study. 2021 , 14, 1959-1968	O
195	Transcription Factor MAFF (MAF Basic Leucine Zipper Transcription Factor F) Regulates an Atherosclerosis Relevant Network Connecting Inflammation and Cholesterol Metabolism. 2021 , 143, 1809-1823	10
194	Multi-trait GWAS of atherosclerosis detects novel pleiotropic loci.	O

193	Triglycerides and Atherosclerosis. 2021 , 77, 3042-3045	O
192	A genome-wide association study identifies 5 loci associated with frozen shoulder and implicates diabetes as a causal risk factor. 2021 , 17, e1009577	O
191	Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies. 2021 , 327, 18-30	10
190	Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis. 2021 , 43, e217-e229	
189	Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts. 2021 ,	0
188	The Relation Between Adult Weight Gain, Adipocyte Volume, and the Metabolic Profile at Middle Age. 2021 , 106, e4438-e4447	1
187	Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. 2021 , 2, e317-e326	7
186	Medium-Chain Triglyceride Oil and Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Trials. 2021 , 151, 2949-2956	2
185	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. 2021 , 10,	6
184	Meat consumption and risk of ischemic heart disease: A systematic review and meta-analysis. 2021 , 1-12	8
183	Evinacumab for treatment of familial hypercholesterolemia. 2021 , 19, 739-751	2
182	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. 2021 , 106, 2828-2839	1
181	Sex-specific trajectories of molecular cardiometabolic trait concentrations through childhood, adolescence and young adulthood: a cohort study.	1
180	Remnant Cholesterol and Cardiovascular Mortality in Patients With Type 2 Diabetes and Incident Diabetic Nephropathy. 2021 , 106, 3546-3554	2
179	Mass Spectrometry for the Monitoring of Lipoprotein Oxidations by Myeloperoxidase in Cardiovascular Diseases. 2021 , 26,	1
178	Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization.	
177	Is a High HDL-Cholesterol Level Always Beneficial?. 2021 , 9,	1
176	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021 , 42, 3227-3337	358

175	Genetically Predicted Insomnia in Relation to 14 Cardiovascular Conditions and 17 Cardiometabolic Risk Factors: A Mendelian Randomization Study. 2021 , 10, e020187	2
174	Individual and combined cardiometabolic morbidities and the subsequent risk of cardiovascular events in Chinese adults. 2021 ,	Ο
173	Vitamin D and Its Metabolites Deficiency in Acute Coronary Syndrome Patients Undergoing Coronary Angiography: A Case-Control Study. 2021 , 17, 471-480	0
172	Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOW-CKD. 2021 , 10, e021731	1
171	A genetic sum score of effect alleles associated with serum lipid concentrations interacts with educational attainment. 2021 , 11, 16541	1
170	Multitrait GWAS to connect disease variants and biological mechanisms. 2021 , 17, e1009713	1
169	Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. 2021, 9,	4
168	Menopausal hormone therapy and women's health: An umbrella review. 2021 , 18, e1003731	11
167	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. 2021 ,	31
166	Association of pre-pandemic high-density lipoprotein cholesterol with risk of COVID-19 hospitalisation and death: The UK Biobank cohort study. 2021 , 23, 101461	4
165	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. 2021 , 9,	3
164	Gene-by-environment modulation of lifespan and weight gain in the murine BXD family. 2021 , 3, 1217-1227	5
163	Genome-Wide Association Study Identifies a Functional Variant Associated With HDL-C (High-Density Lipoprotein Cholesterol) Levels and Premature Coronary Artery Disease. 2021 , 41, 2494-2508	2
162	Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. 2021 , 8,	3
161	Predictors of Carotid Intima-Media Thickness Progression in Adolescents-The EVA-Tyrol Study. 2021 , 10, e020233	1
160	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis 2021 , 7, 560-575	1
159	Mendelian randomization rules out the causal relationship between serum lipids and cholecystitis. 2021 , 14, 224	0
158	Lifestyle Approaches to Lowering Triglycerides. 2021 , 211-223	

157	Association of pre-pandemic high-density lipoprotein cholesterol with risk of COVID-19 hospitalisation and death: the UK Biobank cohort study. 2021 ,	3
156	Causal effects of education on chronic kidney disease: a Mendelian randomization study. 2021 , 14, 1932-1938	1
155	Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. 2021 , 67, 183-196	13
154	Inflammation, remodeling, and other factors affecting HDL cholesterol efflux. 2017, 28, 52-59	39
153	Apolipoprotein B underlies the causal relationship of circulating blood lipids with coronary heart disease.	5
152	Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis.	3
151	Biological age in UK Biobank: biomarker composition and prediction of mortality, coronary heart disease and hospital admissions.	O
150	Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms.	3
149	Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease.	1
148	A functional variant of the SIDT2 gene involved in cholesterol transport is associated with HDL-C levels and premature coronary artery disease.	0
147	Sex-specific associations of adiposity with cardiometabolic traits: multi-life-stage cohort study with repeat metabolomics.	3
146	Mendelian Randomization Analysis Using Mixture Models (MRMix) for Genetic Effect-Size-Distribution Leads to Robust Estimation of Causal Effects.	4
145	An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome.	1
144	Multi-ancestry analysis of gene-sleep interactions in 126,926 individuals identifies multiple novel blood lipid loci that contribute to our understanding of sleep-associated adverse blood lipid profile.	1
143	Evaluating the effects of alcohol and tobacco use on cardiovascular disease using multivariable Mendelian randomization.	1
142	The promise and reality of therapeutic discovery from large cohorts. 2020 , 130, 575-581	4
141	The application of big data to cardiovascular disease: paths to precision medicine. 2020 , 130, 29-38	34
140	Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics. 2021 , 19, 58	8

139	Coronary artery disease, genetic risk and the metabolome in young individuals. 2018, 3, 114	8
138	Inferring causal direction between two traits in the presence of horizontal pleiotropy with GWAS summary data. 2020 , 16, e1009105	7
137	Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study. 2020 , 17, e1003410	21
136	Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions. 2014 , 9, e108891	66
135	Genomic determinants of triglyceride and cholesterol distribution into lipoprotein fractions in the rat. 2014 , 9, e109983	6
134	e2 and aging-related outcomes in 379,000 UK Biobank participants. 2020 , 12, 12222-12233	23
133	Cardioprotective Properties of HDL: Structural and Functional Considerations. 2020 , 27, 2964-2978	15
132	Application of Genome-Wide Association Studies in Coronary Artery Disease. 2019 , 25, 4274-4286	1
131	Two-Sample Mendelian Randomization Study of Lipid levels and Ischemic Heart Disease. 2020 , 50, 940-948	7
130	An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. 2019 , 8,	90
129	Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. 2020 , 9,	8
128	Comparison of Lipid Profile in Patients With and Without Acute Myocardial Infarction. 2019 , 11, e6467	2
127	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. 2021 , 12, 5640	7
126	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. 2021 , 12, 6120	2
125	Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. 2021 , 10,	4
124	A modern approach to dyslipidemia. 2021 ,	10
123	Genetics of Endocrinology. 2016 , 49-68	1
122	Avances en el control lipdico, de la teord a la protica. El reto de la medicina traslacional. 2017 , 17, 24-31	

121	Association of Multiple Genetic Variants with the Extension and Severity of Coronary Artery Disease. 2018 , 110, 16-23	2
120	Response: FACEing reality: productive tensions between our epidemiological questions, methods and mission. 2016 , 45, 1852-1865	15
119	The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: A two-step, two-sample Mendelian randomization study.	
118	Polygenic Link Between Blood Lipids And Amyotrophic Lateral Sclerosis.	O
117	A robust method to estimate regional polygenic correlation identifies heterogeneity in the shared heritability between complex traits.	
116	Treatment of atherogenic dyslipidemia: modern principles and new possibilities. 2017, 8, 51-58	
115	Prioritizing putative influential genes in early life cardiovascular disease susceptibility by applying tissue-specific Mendelian randomization.	
114	Bivariate GWAS scan identifies six novel loci associated with lipid levels and coronary artery disease.	
113	HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW. 2018 , 191-201	
112	Direct estimation of HDL-mediated cholesterol efflux capacity from serum.	
111	Genetic variation in apolipoprotein A-I concentrations and risk of coronary artery disease.	O
110	Genetic determinants of lipids and cardiovascular disease outcomes: a wide-angled Mendelian randomization investigation.	1
109	High-density lipoprotein characteristics and coronary heart disease: a Mendelian randomization study.	
108	Mendelian Randomization with Instrumental Variable Synthesis (IVY).	1
107	Genetics of Height and Risk of Atrial Fibrillation: A Mendelian Randomization Study.	
106	Non-HDL cholesterol as a therapeutic goal. 2019 , 31 Suppl 2, 28-33	1
105	Lipid disorders. 2020 , 2055-2097	
104	Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis. 2020 , 27, 1913-1917	1

103	Valid cardiac biomarkers. Part I. 2020 , 19, 2573	3
102	Metabolic Changes and Their Characterization. 2020 , 35-70	
101	Epidemiology of Atherosclerotic Cardiovascular Disease. 2021 , 91-105	
100	Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!. 2020 ,	O
99	Biomarkers in drug development. 2022 , 323-342	1
98	A Metaphoric Design of Electronic Medical Record (EMR) for Periodic Health Examination Reports. 2022 , 12, 0-0	
97	Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial. 2020 , 22, 108-118	О
96	Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses. 2020 , 50, 91-111	3
95	ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants.	1
94	Inferring Causal Direction Between Two Traits in the Presence of Horizontal Pleiotropy with GWAS Summary Data.	
93	Effects of apolipoprotein B on the lifespan and risks of major disease including type 2 diabetes: a Mendelian randomization analysis using outcomes in first-degree relatives.	
92	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics.	1
91	A genome wide association study of frozen shoulder identifies a common variant of WNT7B and diabetes as causal risk factors.	
90	Acute Running and Coronary Heart Disease Risk Markers in Male Cigarette Smokers and Nonsmokers: A Randomized Crossover Trial. 2021 , 53, 1021-1032	1
89	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. 2016 , 23, 169-73	3
88	[Investigating the causal relationship between human blood metabolites and coronary artery disease using two-sample Mendelian randomization]. 2021 , 41, 272-278	
87	Sex differences in the non-linear association between BMI and LDL cholesterol in middle-aged and older adults: findings from two nationally representative surveys in China. 2021 , 20, 162	О
86	Apolipoprotein E Content of Very Low-density Lipoprotein Limits Lipoprotein Lipase-mediated Triglyceride Hydrolysis. 2021 , 100157	0

85	Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease 2021 ,	1
84	HDL colesterol, protector de enfermedad cardiovascular: calidad vs. cantidad. 2016 , 5, 95-108	
83	Associations of lipoprotein particle profile and objectively measured physical activity and sedentary time in schoolchildren: a prospective cohort study 2022 , 19, 5	0
82	Sex-specific associations of adiposity with cardiometabolic traits in the UK: A multi-life stage cohort study with repeat metabolomics 2022 , 19, e1003636	o
81	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design 2022 ,	2
80	Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins 2022 , 24, 1	O
79	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease 2021 , ATVBAHA121317181	О
78	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci 2021 , 12, 787545	
77	HDL maturation and remodelling 2022, 1867, 159119	1
76	Mendelian randomization. 2022 , 2,	10
76 75	Mendelian randomization. 2022, 2, High-density lipoprotein cholesterol [Friend or enemy?. 2022, 103, 79-88	10
		10
75	High-density lipoprotein cholesterol [friend or enemy?. 2022, 103, 79-88 Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic	
75 74	High-density lipoprotein cholesterol [friend or enemy?. 2022, 103, 79-88 Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis 2021, 8, 774418 Investigating Linear and Nonlinear Associations of LDL Cholesterol With Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease and All-Cause Mortality: A Prospective and Mendelian	
75 74 73	High-density lipoprotein cholesterol [Friend or enemy?. 2022, 103, 79-88 Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis 2021, 8, 774418 Investigating Linear and Nonlinear Associations of LDL Cholesterol With Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease and All-Cause Mortality: A Prospective and Mendelian Randomization Study. Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis	
75 74 73 72	High-density lipoprotein cholesterol [friend or enemy?. 2022, 103, 79-88 Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis 2021, 8, 774418 Investigating Linear and Nonlinear Associations of LDL Cholesterol With Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease and All-Cause Mortality: A Prospective and Mendelian Randomization Study. Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L 2022, 33197221075861	1
75 74 73 72 71	High-density lipoprotein cholesterol (Friend or enemy?. 2022, 103, 79-88 Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis 2021, 8, 774418 Investigating Linear and Nonlinear Associations of LDL Cholesterol With Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease and All-Cause Mortality: A Prospective and Mendelian Randomization Study. Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L 2022, 33197221075861 Cholesterol measurement and current guidelines. 2022, 68, 54-57 Calculating Polygenic Risk Scores (PRS) in UK Biobank: A Practical Guide for Epidemiologists 2022,	0

67	Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19 2022 , 18, e1010042	2
66	Metabolic associations with stroke, dementia, and imaging markers of cerebral small vessel disease: a comprehensive metabolomics study.	
65	Nonparametric bounds in two-sample summary-data Mendelian randomization: Some cautionary tales for practice 2022 ,	O
64	High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients 2022 , 31, 106448	
63	Sex-Specific U-Shaped Relationships Between High-Density Lipoprotein Cholesterol Levels and 10-year Major Adverse Cardiovascular Events: A Nationwide Cohort Study of 5.7 Million South Koreans 2022 , 42, 415-427	2
62	Changes in plasma levels of per- and polyfluoroalkyl substances (PFAS) are associated with changes in plasma lipids - A longitudinal study over 10 years 2022 , 112903	1
61	Anthocyanins, Anthocyanin-Rich Berries, and Cardiovascular Risks: Systematic Review and Meta-Analysis of 44 Randomized Controlled Trials and 15 Prospective Cohort Studies 2021 , 8, 747884	6
60	Modification of High-Density Lipoprotein Functions by Diet and Other Lifestyle Changes: A Systematic Review of Randomized Controlled Trials 2021 , 10,	О
59	Systems epidemiology of metabolomics measures reveals new relationships between lipoproteins and other small molecules 2021 , 18, 1	О
58	Classical risk factors for primary coronary artery disease from an aging perspective through Mendelian Randomization 2021 , 1	О
57	Hypolipidemic Pharmacotherapy from the Latest Recommendations. 2020 , 97-107	
56	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events 2022 , 54, 1036-1046	1
55	HDL particle subclasses in statin treated patients with peripheral artery disease predict long-term survival 2022 ,	
54	Deep Lipidomics in Human Plasma - Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation 2022 ,	3
53	Gull ESC 2021 sobre la prevencili de la enfermedad cardiovascular en la prlitica clilica. 2022,	1
52	Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study.	
51	Association of assisted reproductive technology with long-term offspring cardiometabolic health: a multi-cohort study.	
50	Mendelian randomization in pharmacogenomics: The unforeseen potentials 2022 , 150, 112952	O

49	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. 2022 , 21, 3235	11
48	[Novel options to maximize oral lipid lowering treatment : Role of bempedoic acid in combination treatment] 2022 , 1	
47	Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations 2022 ,	2
46	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia 2022 , 101161ATVBAHA122317790	1
45	Protein-based HDL subspecies: Rationale and association with cardiovascular disease, diabetes, stroke, and dementia. 2022 , 1867, 159182	0
44	Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies. 2022 , 4, 100075	O
43	Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations. 2022 , 14,	Ο
42	Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. 2022 , 21,	Ο
41	Low-Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific. 2022 , 11,	1
40	Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke. 9,	
39	Circulating metabolites associated with incident myocardial infarction and stroke: A prospective cohort study of 90 438 participants.	
38	Phenome-wide Mendelian randomization study of plasma triglycerides and 2,600 disease traits.	
37	Gene-diet interactions and cardiovascular diseases: a systematic review of observational and clinical trials. 2022 , 22,	О
36	Hypertension and Hypercholesterolemia: Let⊠ Make Therapy Easy and Efficient. 2022 , 111, 558-563	
35	A mendelian randomization study with populations of European ancestry rules out a causal relationship between inflammatory bowel disease and colorectal cancer. 13,	1
34	An Overview of Methods and Exemplars of the Use of Mendelian Randomisation in Nutritional Research. 2022 , 14, 3408	1
33	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals.	0
32	Systematic evaluation for the causal effects of blood metabolites on osteoporosis: Genetic risk score and Mendelian randomization. 10,	Ο

31	High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. 2022 , 79, 2355-2363	О
30	Comparison between biomarkers high-sensitivity C-Reactive protein and N-Terminal probrain natriuretic peptide in patients with myocardial infarction. 2022 , 17, 78	О
29	Age-dependent sex differences in cardiometabolic risk factors. 2022 , 1, 844-854	1
28	Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation. 2022 ,	0
27	Statistical methods for cis -Mendelian randomization with two-sample summary-level data.	0
26	Review of recent clinical trials and their impact on the treatment of hypercholesterolemia. 2022,	2
25	Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults. 2022 , 2,	О
24	The role of metabolic syndrome factors in the pathogenesis of respiratory disorders.	O
23	Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology. 2023 , 148, 107137	0
22	Assessing the Causal Effect of Blood Pressure on Renal Cancer in the UK Biobank via Mendelian Randomisation.	O
21	Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis. 2022, 23, 16224	1
20	Current Understanding of Diabetic Dyslipidemia: A Review.	О
19	Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization. 2023 , 22,	О
18	Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes. 2023 , 3,	1
17	The relationship between high density lipoprotein cholesterol and sepsis: A clinical and genetic approach.	O
16	High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases. 000331972311574	O
15	The role of (pro)renin receptor and its soluble form in cardiovascular diseases. 10,	О
14	Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis. 2023 , 44, 1464-1473	O

CITATION REPORT

13	Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study. 2023 , 13, 244	1
12	Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. 2023 , 12, 1382	O
11	Associations between types and sources of dietary carbohydrates and cardiovascular disease risk: a prospective cohort study of UK Biobank participants. 2023 , 21,	O
10	Differences in HDL-related mortality risk between individuals with and without hypertension: a prospective cohort study in UK Biobank.	O
9	Associations between polyunsaturated fatty acid concentrations and Parkinson disease: A two-sample Mendelian randomization study. 15,	O
8	Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. 2023 , 46, 643-656	O
7	Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study. 2023 , 90, 104503	O
6	A Review of Low-Density Lipoprotein-Lowering Diets in the Age of Anti-Sense Technology. 2023 , 15, 1249	O
5	Mendelian Randomization Analysis Provides Insights into the Pathogenesis of Serum Levels of Branched-Chain Amino Acids in Cardiovascular Disease. 2023 , 13, 403	O
4	Robust multivariable Mendelian randomization based on constrained maximum likelihood. 2023 , 110, 592-605	O
3	Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits. 12,	О
2	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease.	O
1	Postprandial metabolic responses to high-fat feeding in healthy adults following ingestion of oolong tea-derived polymerized polyphenols: a randomized, double-blinded, placebo-controlled crossover study. 2023 ,	O